Description: PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets. This segment includes subsidiary companies, which include Vedanta Biosciences, Inc., Gelesis, Inc., Akili Interactive Lab, Inc., Tal Medical, Inc., Karuna Pharmaceuticals, Inc., Entrega Inc. and Follica Incorporated. Businesses in the project phase businesses segment are those whose activities are focused on financing, sourcing and creating new product candidates and newly created businesses whose technologies are in the process of validation. This segment includes subsidiary companies, which include The Sync Project Inc., Sonde Health, Inc., Commense Inc., Alivio Therapeutics, Inc., Vor Biopharma Inc., Enlight Biosciences, LLC, Mandara Sciences, LLC and Knode Inc.
Home Page: www.puretechhealth.com
PRTC Technical Analysis
6 Tide Street
Boston,
MA
02210
United States
Phone:
617 482 2333
Officers
Name | Title |
---|---|
Ms. Daphne Zohar | Founder, CEO & Exec. Director |
Dr. Bharatt M. Chowrira J.D., Ph.D. | Pres, Sec., Chief Bus. Fin. & Operating Officer and Exec. Director |
Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD | Co-Founder & Non-Exec. Director |
Dr. Bennett M. Shapiro M.D. | Co-Founder & Board Advisor |
Dr. David R. Elmaleh Ph.D. | Co-Founder & Sr. Advisor |
Dr. Joseph B. Bolen | Chief Scientific Officer |
Ms. Allison Mead Talbot | Head of Communications & Investor Relations |
Mr. Spencer Ball | Sr. VP of HR |
Dr. Eric Elenko Ph.D. | Chief Innovation & Strategy Officer |
Ms. Aleksandra Filipovic M.D., Ph.D. | Head of Oncology |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Life Sciences Tools & Services |
GIC Sub-Industry: | Life Sciences Tools & Services |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 1.675 |
Price-to-Sales TTM: | 43.4044 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 95 |